Clinical Trials Logo

Clinical Trial Summary

Safety and efficacy of DE-105 ophthalmic solution in patients with persistent corneal epithelial defect will be evaluated. Dose-dependent efficacy will be evaluated as well.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Persistent Corneal Epithelial Defect

NCT number NCT00988494
Study type Interventional
Source Santen Pharmaceutical Co., Ltd.
Contact
Status Completed
Phase Phase 2
Start date September 2009

See also
  Status Clinical Trial Phase
Completed NCT03687632 - ST266 Eye Drops for the Treatment of Persistent Corneal Epithelial Defects Phase 2
Recruiting NCT05966493 - A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED Phase 2/Phase 3
Completed NCT05436288 - A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Epithelial Defects Phase 2
Recruiting NCT05727878 - Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED Phase 2
Completed NCT02979912 - Autologous Platelet Lysate in Corneal Epithelial Defects Phase 1/Phase 2
Terminated NCT05066698 - ST266 Eyedrops for the Treatment of Persistent Corneal Epithelial Defects Phase 2
Withdrawn NCT05172349 - Use of a Biological Lens of Amniotic Membrane (LV-Visio-AMTRIX) in the Treatment of Trophic Ulcers Phase 2